Literature DB >> 29296373

Intensity-modulated fractionated stereotactic radiotherapy with reduced margin for high grade gliomas: dosimetric analysis of sparing optic nerve & chiasm.

Hyeon Kang Koh1, Chae-Yong Kim2, Jung Ho Han2, Yu Jung Kim3, Hak Jae Kim1, Jae Sung Kim4, In Ah Kim4.   

Abstract

The aim of this study was to evaluate the potential advantage of intensity modulation fractionated stereotactic radiotherapy (IM-FSRT) for sparing the optic nerve and chiasm in the management of anaplastic astrocytoma (AA) or glioblastoma (GBM). Clinical data of 16 patients with high grade gliomas were retrospectively reviewed. All patients had tumors close to the optic chiam that prohibited the full dose radiation therapy. The patients were treated with either IM-FSRT in conjunction with external beam radiation or IM-FSRT only to a total dose of 60 Gy. The final dosimetric analysis was performed. The estimated average maximum optic nerve and chiasm dose 48.6±5.0 Gy (range, 34.2-55.9). Conformity index reached as high as 0.98, and inhomogeneity coefficient was low enough to deliver the prescribed radiation dose. IM-FSRT showed excellent dose conformality to the target volume with superior normal tissue sparing effect. High precision therapy such as IM-FSRT could be a reliable treatment technique for the patients with AA or GBM for a maximal sparing of optic apparatus.

Entities:  

Keywords:  fractionated stereotactic radiotherapy; intensity modulation; malignant glioma; optic nerve and chiasm sparing

Year:  2013        PMID: 29296373      PMCID: PMC5658840     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  31 in total

1.  Fractionated stereotactic intensity-modulated radiotherapy (FS-IMRT) for small acoustic neuromas.

Authors:  Martin Fuss; Bill J Salter; Amir Sadeghi; Dennis G Vollmer; James M Hevezi; Terence S Herman
Journal:  Med Dosim       Date:  2002       Impact factor: 1.482

2.  Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?

Authors:  Ulrich Hermanto; Erik K Frija; Mingfwu J Lii; Eric L Chang; Anita Mahajan; Shiao Y Woo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-08       Impact factor: 7.038

3.  Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.

Authors:  Il Han Kim; Chul-Kee Park; Dae Seog Heo; Chae-Yong Kim; Chang Hun Rhee; Do-Hyun Nam; Seung Hoon Lee; Jung Ho Han; Se-Hoon Lee; Tae Min Kim; Dong-Wan Kim; Jeong Eun Kim; Sun Ha Paek; Dong Gyu Kim; In Ah Kim; Yu Jung Kim; Jee Hyun Kim; Byung-Joo Park; Hee-Won Jung
Journal:  J Neurooncol       Date:  2010-11-04       Impact factor: 4.130

4.  Quality assurance in fractionated stereotactic radiotherapy.

Authors:  A P Warrington; R W Laing; M Brada
Journal:  Radiother Oncol       Date:  1994-03       Impact factor: 6.280

5.  Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.

Authors:  Mario Balducci; Giuseppina Apicella; Stefania Manfrida; Annunziato Mangiola; Alba Fiorentino; Luigi Azario; Giuseppe Roberto D'Agostino; Vincenzo Frascino; Nicola Dinapoli; Giovanna Mantini; Alessio Albanese; Pasquale de Bonis; Silvia Chiesa; Vincenzo Valentini; Carmelo Anile; Numa Cellini
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

6.  EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.

Authors:  Brigitta G Baumert; Michael Brada; Jacques Bernier; Rolf D Kortmann; Cary Dehing-Oberije; Laurence Collette; J Bernard Davis
Journal:  Radiother Oncol       Date:  2008-04-30       Impact factor: 6.280

Review 7.  Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.

Authors:  Kwan Ho Cho; Joo-Young Kim; Seung Hoon Lee; Heon Yoo; Sang Hoon Shin; Sung Ho Moon; Tae Hyun Kim; Kyung Hwan Shin; Myonggeun Yoon; Doo-Hyun Lee; Hong Ryull Pyo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-25       Impact factor: 7.038

8.  Radiotherapy of malignant gliomas: comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated technique and 3D conformal technique.

Authors:  Daniela Wagner; Hans Christiansen; Hendrik Wolff; Hilke Vorwerk
Journal:  Radiother Oncol       Date:  2009-11-10       Impact factor: 6.280

9.  Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas.

Authors:  Brigitta G Baumert; Johannes Lutterbach; René Bernays; J Bernard Davis; Frank L Heppner
Journal:  Radiother Oncol       Date:  2003-05       Impact factor: 6.280

10.  Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy.

Authors:  Kiyoshi Nakamatsu; Minoru Suzuki; Yasumasa Nishimura; Shuichi Kanamori; Ryuta Koike; Toru Shibata; Naoya Shintani; Masahiko Okumura; Kaoru Okajima; Fumiharu Akai
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.